A5032324484- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Uterine Myomas and Treatments
- Cervical Cancer and HPV Research
- Toxin Mechanisms and Immunotoxins
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Gynecological conditions and treatments
- Circular RNAs in diseases
- Reproductive System and Pregnancy
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- HER2/EGFR in Cancer Research
- Surgical site infection prevention
- Effects and risks of endocrine disrupting chemicals
- Advances in Oncology and Radiotherapy
Oklahoma State University Oklahoma City
2020-2025
University of Oklahoma
2019-2025
University of Oklahoma Health Sciences Center
2018-2025
OU Health
2024-2025
Oklahoma City University
2020-2024
OU Health Stephenson Cancer Center
2020-2024
Yale University
2022
University of Pennsylvania
2015-2020
Hospital of the University of Pennsylvania
2020
Pennsylvania Hospital
2015-2020
Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought confirm proportion patients with at least 1 actionable alteration whether use molecularly targeted was associated improved survival metastatic cancer. A multidisciplinary consortium formed study treatment therapies Tumor therapeutic decisions were physician's recommendations. The abstracted data included age, stage,...
Importance Three-year pelvic recurrence rate in women with low-risk cervical carcinoma was not inferior following simple hysterectomy (SH) vs modified radical (MRH) or (RH) the Simple Hysterectomy and Pelvic Node Assessment randomized clinical trial, but survival analysis of trial underpowered. Objective To evaluate long-term SH MRH RH. Design, Setting, Participants This cohort study included undergoing SH, RH US Commission on Cancer–accredited facilities participating National Cancer...
Targeted therapies have changed the treatment landscape in gynecologic cancer. Studies released over past year led to incorporation of immunotherapy (IO) into for all patients with endometrial and cervical cancers at some point during their disease course. Poly(ADP-ribose) polymerase (PARP) inhibitors continue play a role women ovarian carcinoma, particularly homologous repair deficient tumors. Furthermore, benefit PARP challenging subgroups continues be elucidated. Biomarker identification...
The purpose of the study was to compare effectiveness PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status [BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig)] advanced ovarian cancer.
Abstract Purpose: We assessed the efficacy of anti-PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared to standard-of-care chemotherapy (SOC) platinum-resistant epithelial ovarian cancer (PROC) patients, prior bevacizumab. Patients Methods: NRG-GY023 was first, randomized 4-arm superiority phase II trial enrolling high-grade serous/endometrioid or clear cell PROC patients bevacizumab exposure. were 1:2:2:2 SOC (weekly paclitaxel, topotecan pegylated liposomal...
Background Despite advances in cervical cancer (CC) prevention, detection, and treatment the US, health disparities persist, disproportionately affecting underserved populations or regions. This study analyzes geographical distribution of both CC recurrent/metastatic (r/mCC) US explores potential risk factors higher disease burden to inform strategies address r/mCC. Methods We estimated screening rates, as well (number patients with diagnosis per 100,000 eligible enrollees) r/mCC (proportion...
To investigate IMT use and survival in real-world stage IVB cervical cancer patients outside randomized clinical trials.
PURPOSE COVID-19 is a rapidly emerging worldwide pandemic that has drastically changed health care across the United States. Oncology patients are especially vulnerable. Novel point-of-care resources may be useful to disseminate peer-reviewed information from oncology experts nationwide. We describe our initial experience with distributing this through private, curated, virtual collaboration question-and-answer (Q&A) platform for oncologists. METHODS The Q&A database was queried...